
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/747638/publications.pdf Version: 2024-02-01



KINIS RANSO

#	Article	IF	CITATIONS
1	Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial. Lancet, The, 2020, 396, 1413-1421.	13.7	226
2	Prognostic value of PINP, bone alkaline phosphatase, CTX-I, and YKL-40 in patients with metastatic prostate carcinoma. Prostate, 2006, 66, 503-513.	2.3	112
3	Prostate artery embolisation for benign prostatic hyperplasia: a systematic review and meta-analysis. European Radiology, 2019, 29, 287-298.	4.5	98
4	Enzalutamide Antitumour Activity Against Metastatic Castration-resistant Prostate Cancer Previously Treated with Docetaxel and Abiraterone: A Multicentre Analysis. European Urology, 2015, 68, 317-324.	1.9	96
5	First-in-human uPAR PET: Imaging of Cancer Aggressiveness. Theranostics, 2015, 5, 1303-1316.	10.0	92
6	ERG Protein Expression in Diagnostic Specimens Is Associated with Increased Risk of Progression During Active Surveillance for Prostate Cancer. European Urology, 2014, 66, 851-860.	1.9	75
7	Does Cytoreductive Prostatectomy Really Have an Impact on Prognosis in Prostate Cancer Patients with Low-volume Bone Metastasis? Results from a Prospective Case-Control Study. European Urology Focus, 2017, 3, 646-649.	3.1	72
8	Postdiagnosis Statin Use and Mortality in Danish Patients With Prostate Cancer. Journal of Clinical Oncology, 2017, 35, 3290-3297.	1.6	69
9	Efficacy of recreational football on bone health, body composition, and physical functioning in men with prostate cancer undergoing androgen deprivation therapy: 32-week follow-up of the FC prostate randomised controlled trial. Osteoporosis International, 2016, 27, 1507-1518.	3.1	61
10	Safety, Dosimetry, and Tumor Detection Ability of <sup>68</sup> Ga-NOTA-AE105: First-in-Human Study of a Novel Radioligand for uPAR PET Imaging. Journal of Nuclear Medicine, 2017, 58, 379-386.	5.0	58
11	Trends in incidence and 5â€year mortality in men with newly diagnosed, metastatic prostate cancer—A populationâ€based analysis of 2 national cohorts. Cancer, 2018, 124, 2931-2938.	4.1	58
12	Proteogenomic Characterization of Patient-Derived Xenografts Highlights the Role of REST in Neuroendocrine Differentiation of Castration-Resistant Prostate Cancer. Clinical Cancer Research, 2019, 25, 595-608.	7.0	55
13	The Movember campaign: Impact on referral patterns and diagnosis of prostate cancer. Scandinavian Journal of Public Health, 2016, 44, 228-232.	2.3	54
14	Risk of prostate cancer diagnosis and mortality in men with a benign initial transrectal ultrasound-guided biopsy set: a population-based study. Lancet Oncology, The, 2017, 18, 221-229.	10.7	54
15	Football training in men with prostate cancer undergoing androgen deprivation therapy: activity profile and short-term skeletal and postural balance adaptations. European Journal of Applied Physiology, 2016, 116, 471-480.	2.5	48
16	Short-term morbidity and mortality following radical cystectomy: a systematic review. BMJ Open, 2021, 11, e043266.	1.9	48
17	Effect of a 2-year home-based endurance training intervention on physiological function and PSA doubling time in prostate cancer patients. Cancer Causes and Control, 2016, 27, 165-174.	1.8	45
18	SPCG-15: a prospective randomized study comparing primary radical prostatectomy and primary radiotherapy plus androgen deprivation therapy for locally advanced prostate cancer. Scandinavian Journal of Urology, 2018, 52, 313-320.	1.0	40

#	Article	IF	CITATIONS
19	Lower Urinary Tract Symptoms: A Population Survey Using the Danish Prostatic Symptom Score (DAN-PSS) Questionnaire. Scandinavian Journal of Urology and Nephrology, 1999, 33, 94-99.	1.4	37
20	Prostate cancer in Denmark 1978–2009 — trends in incidence and mortality. Acta Oncológica, 2013, 52, 831-836.	1.8	36
21	Improved survival for patients with de novo metastatic prostate cancer in the last 20 years. European Journal of Cancer, 2017, 72, 20-27.	2.8	34
22	Football Compared with Usual Care in Men with Prostate Cancer (FC Prostate Community Trial): A Pragmatic Multicentre Randomized Controlled Trial. Sports Medicine, 2019, 49, 145-158.	6.5	33
23	Psychological distress following fecal occult blood test in colorectal cancer screening – a population-based study. Scandinavian Journal of Gastroenterology, 2010, 45, 1211-1216.	1.5	31
24	Community-Based Recreational Football: A Novel Approach to Promote Physical Activity and Quality of Life in Prostate Cancer Survivors. International Journal of Environmental Research and Public Health, 2014, 11, 5567-5585.	2.6	31
25	Diagnostic characteristics of lethal prostate cancer. European Journal of Cancer, 2017, 84, 18-26.	2.8	31
26	The "Football is Medicine―platform—scientific evidence, largeâ€scale implementation of evidenceâ€based concepts and future perspectives. Scandinavian Journal of Medicine and Science in Sports, 2018, 28, 3-7.	2.9	31
27	Community-based football in men with prostate cancer: 1-year follow-up on a pragmatic, multicentre randomised controlled trial. PLoS Medicine, 2019, 16, e1002936.	8.4	30
28	Vaccination against RhoC induces long-lasting immune responses in patients with prostate cancer: results from a phase I/II clinical trial. , 2020, 8, e001157.		28
29	Danish Prostate Cancer Registry – methodology and early results from a novel national database. Clinical Epidemiology, 2016, Volume 8, 351-360.	3.0	25
30	Low-dose aspirin or other nonsteroidal anti-inflammatory drug use and prostate cancer risk: a nationwide study. Cancer Causes and Control, 2016, 27, 1067-1079.	1.8	24
31	PSA testing without clinical indication for prostate cancer in relation to socio-demographic and clinical characteristics in the Danish Diet, Cancer and Health Study. Acta Oncológica, 2013, 52, 1609-1614.	1.8	23
32	Recision of a Patient-Weighted Symptom Score in Prostatism. Scandinavian Journal of Urology and Nephrology, 1994, 28, 71-75.	1.4	21
33	Socioeconomic position and mortality among patients with prostate cancer: influence of mediating factors. Acta Oncológica, 2017, 56, 563-568.	1.8	21
34	Palliative Prostate Artery Embolization for Prostate Cancer: A Case Series. CardioVascular and Interventional Radiology, 2019, 42, 1405-1412.	2.0	21
35	Active Surveillance for Localized Prostate Cancer: Nationwide Observational Study. Journal of Urology, 2019, 201, 520-527.	0.4	21
36	Long-term results of surgery for incarcerated groin hernia. Acta Chirurgica Scandinavica, 1989, 155, 583-5.	0.2	21

#	Article	IF	CITATIONS
37	Quality assessment of prostate cancer reports to the Danish Cancer Registry. Acta Oncológica, 2016, 55, 24-29.	1.8	20
38	Vitamin D levels and the risk of prostate cancer and prostate cancer mortality. Acta Oncológica, 2021, 60, 316-322.	1.8	20
39	The impact of the 2005 International Society of Urological Pathology consensus guidelines on Gleason grading – a matchedâ€pair analysis. BJU International, 2016, 117, 883-889.	2.5	19
40	Football training over 5 years is associated with preserved femoral bone mineral density in men with prostate cancer. Scandinavian Journal of Medicine and Science in Sports, 2018, 28, 61-73.	2.9	19
41	Open vs robotâ€assisted radical cystectomy (BORARC): a doubleâ€blinded, randomised feasibility study. BJU International, 2022, 130, 102-113.	2.5	19
42	Survival benefit of early androgen receptor inhibitor therapy in locally advanced prostate cancer: Long-term follow-up of the SPCG-6 study. European Journal of Cancer, 2015, 51, 1283-1292.	2.8	18
43	The risk of biochemical recurrence for intermediate-risk prostate cancer after radical prostatectomy. Scandinavian Journal of Urology, 2017, 51, 450-456.	1.0	18
44	Seminal plasma PSA in spinal cord injured men: a preliminary report. Spinal Cord, 1998, 36, 771-773.	1.9	17
45	Molecular Profiling of Docetaxel-Resistant Prostate Cancer Cells Identifies Multiple Mechanisms of Therapeutic Resistance. Cancers, 2021, 13, 1290.	3.7	17
46	Morbidity and Days Alive and Out of Hospital Within 90 Days Following Radical Cystectomy for Bladder Cancer. European Urology Open Science, 2021, 28, 1-8.	0.4	17
47	Elevated miR-615-3p Expression Predicts Adverse Clinical Outcome and Promotes Proliferation and Migration of Prostate Cancer Cells. American Journal of Pathology, 2019, 189, 2377-2388.	3.8	16
48	Prostate Artery Embolization for Lower Urinary Tract Symptoms in Men Unfit for Surgery. Diagnostics, 2019, 9, 46.	2.6	16
49	Urokinase-Type Plasminogen Activator Receptor (uPAR) PET/MRI of Prostate Cancer for Noninvasive Evaluation of Aggressiveness: Comparison with Gleason Score in a Prospective Phase 2 Clinical Trial. Journal of Nuclear Medicine, 2021, 62, 354-359.	5.0	16
50	Systematic review: does endocrine therapy prolong survival in patients with prostate cancer?. Scandinavian Journal of Urology, 2016, 50, 135-143.	1.0	15
51	Educational level and the risk of depression after prostate cancer. Acta Oncológica, 2019, 58, 722-729.	1.8	15
52	Use of Low-Dose Aspirin and Mortality After Prostate Cancer Diagnosis. Annals of Internal Medicine, 2019, 170, 443.	3.9	15
53	Effectiveness of community-based football compared to usual care in men with prostate cancer: Protocol for a randomised, controlled, parallel group, multicenter superiority trial (The FC Prostate) Tj ETQq1 1	0.78246814	rgBT4Overlac
54	Differences in survival from prostate cancer in Denmark, Iceland and Sweden. European Journal of Cancer, 2013, 49, 1984-1992.	2.8	13

#	Article	IF	CITATIONS
55	Anastomotic complications after robot-assisted laparoscopic and open radical prostatectomy. Scandinavian Journal of Urology, 2016, 50, 274-279.	1.0	13
56	Association between PSA kinetics and cancer-specific mortality in patients with localised prostate cancer: analysis of the placebo arm of the SPCG-6 study. Annals of Oncology, 2016, 27, 460-466.	1.2	13
57	Risk of Depression After Radical Prostatectomy—A Nationwide Registry-based Study. European Urology Oncology, 2021, 4, 601-608.	5.4	13
58	The "Wallstent― A New Stent for the Treatment of Urethral Strictures. Scandinavian Journal of Urology and Nephrology, 1993, 27, 247-250.	1.4	12
59	Associations between statin use and progression in men with prostate cancer treated with primary androgen deprivation therapy. Scandinavian Journal of Urology, 2017, 51, 464-469.	1.0	12
60	Active surveillance for localized prostate cancer: update of a prospective single-center cohort. Scandinavian Journal of Urology, 2018, 52, 14-19.	1.0	12
61	Predictive value of combined analysis of proâ€ <scp>NPY</scp> and <scp>ERG</scp> in localized prostate cancer. Apmis, 2018, 126, 804-813.	2.0	12
62	Active Surveillance Versus Radical Prostatectomy in Favorable-risk Localized Prostate Cancer. Clinical Genitourinary Cancer, 2019, 17, e814-e821.	1.9	12
63	The predictive value of ERG protein expression for development of castration-resistant prostate cancer in hormone-naÃ <sup>-</sup> ve advanced prostate cancer treated with primary androgen deprivation therapy. Prostate, 2015, 75, 1499-1509.	2.3	11
64	The Danish Prostate Cancer Database. Clinical Epidemiology, 2016, Volume 8, 649-653.	3.0	11
65	Copenhagen uPAR prostate cancer (CuPCa) database: protocol and early results. Biomarkers in Medicine, 2016, 10, 209-216.	1.4	11
66	Clinical characteristics and primary management of patients diagnosed with prostate cancer between 2007 and 2013: status from a Danish primary referral center. Acta Oncológica, 2016, 55, 1456-1460.	1.8	10
67	A single-center experience with abiraterone as treatment for metastatic castration-resistant prostate cancer. Urologic Oncology: Seminars and Original Investigations, 2016, 34, 291.e1-291.e7.	1.6	10
68	A Nationwide Analysis of Risk of Prostate Cancer Diagnosis and Mortality following an Initial Negative Transrectal Ultrasound Biopsy with Long-Term Followup. Journal of Urology, 2022, 208, 100-108.	0.4	10
69	Cytoreductive prostatectomy in metastatic prostate cancer: a systematic review. Scandinavian Journal of Urology, 2018, 52, 1-7.	1.0	9
70	Finasteride treatment and male breast cancer: a registerâ€based cohort study in four Nordic countries. Cancer Medicine, 2018, 7, 254-260.	2.8	9
71	Risk of cardiovascular events in men treated for prostate cancer compared with prostate cancer-free men. British Journal of Cancer, 2019, 120, 1067-1074.	6.4	9
72	Educational level and first-time PSA testing in general practice. Scandinavian Journal of Urology, 2019, 53, 275-281.	1.0	9

#	Article	IF	CITATIONS
73	ERG protein expression over time: from diagnostic biopsies to radical prostatectomy specimens in clinically localised prostate cancer. Journal of Clinical Pathology, 2015, 68, 788-794.	2.0	8
74	Prognostic implications of 2005 Gleason grade modification. Populationâ€based study of biochemical recurrence following radical prostatectomy. Journal of Surgical Oncology, 2016, 114, 664-670.	1.7	8
75	Radical prostatectomy in Denmark: Survival analysis and temporal trends in clinicopathological parameters with up to 20 years of follow-up. Surgical Oncology, 2017, 26, 21-27.	1.6	8
76	The prognostic impact of incidental prostate cancer following radical cystoprostatectomy: a nationwide analysis. Scandinavian Journal of Urology, 2018, 52, 358-363.	1.0	8
77	Finasteride Use and Risk of Male Breast Cancer: A Case–Control Study Using Individual-Level Registry Data from Denmark, Finland, and Sweden. Cancer Epidemiology Biomarkers and Prevention, 2019, 28, 980-986.	2.5	8
78	Validation of the four-miRNA biomarker panel MiCaP for prediction of long-term prostate cancer outcome. Scientific Reports, 2020, 10, 10704.	3.3	8
79	Itraconazole Reverts ABCB1-Mediated Docetaxel Resistance in Prostate Cancer. Frontiers in Pharmacology, 0, 13, .	3.5	8
80	The CPC Risk Calculator: A New App to Predict Prostate-specific Antigen Recurrence During Follow-up After Radical Prostatectomy. European Urology Focus, 2018, 4, 360-368.	3.1	7
81	Safety and Effects of Football in Skeletal Metastatic Prostate Cancer: a Subgroup Analysis of the FC Prostate Community Randomised Controlled Trial. Sports Medicine - Open, 2021, 7, 27.	3.1	7
82	Risk of depression after diagnostic prostate cancer workup–ÂA nationwide, registryâ€based study. Psycho-Oncology, 2021, 30, 1939-1947.	2.3	7
83	Poor association between the progression criteria in active surveillance and subsequent histopathological findings following radical prostatectomy. Scandinavian Journal of Urology, 2015, 49, 354-359.	1.0	5
84	Predictive value of AZGP1 following radical prostatectomy for prostate cancer: a cohort study and meta-analysis. Journal of Clinical Pathology, 2019, 72, 696-704.	2.0	5
85	Patterns of finasteride use in the male populations of four Nordic countries: A cross-national drug utilization study. Scandinavian Journal of Urology, 2016, 50, 220-227.	1.0	4
86	Isolated testicular prostate cancer metastasis. Scandinavian Journal of Urology, 2017, 51, 426-427.	1.0	4
87	Temporal Trends in Clinical and Pathological Characteristics for Men Undergoing Radical Prostatectomy Between 1995 and 2013 at Rigshospitalet, Copenhagen, Denmark, and Stanford University Hospital, United States. Clinical Genitourinary Cancer, 2018, 16, e181-e192.	1.9	4
88	5hmC Level Predicts Biochemical Failure Following Radical Prostatectomy in Prostate Cancer Patients with ERG Negative Tumors. International Journal of Molecular Sciences, 2019, 20, 1025.	4.1	4
89	Novel functions of the luteinizing hormone/chorionic gonadotropin receptor in prostate cancer cells and patients. PLoS ONE, 2020, 15, e0238814.	2.5	4
90	Effectiveness of Docetaxel for Metastatic Hormone-sensitive Prostate Cancer in Clinical Practice. European Urology Open Science, 2021, 24, 25-33.	0.4	4

#	Article	lF	CITATIONS
91	Basal Cell Carcinoma of Prostate With MSMB–NCOA4 Fusion and a Probable Basal Cell Carcinoma In Situ: Case Report. International Journal of Surgical Pathology, 2021, 29, 850-855.	0.8	4
92	Detection of Clinically Significant Prostate Cancer by Systematic TRUS-Biopsies in a Population-Based Setting Over a 20 Year Period. Urology, 2021, 155, 20-25.	1.0	4
93	What is the risk of prostate cancer mortality following negative systematic TRUS-guided biopsies? A systematic review. BMJ Open, 2020, 10, e040965.	1.9	4
94	The need for hospital care of patients with clinically localized prostate cancer managed by noncurative intent: a population based registry study. Journal of Urology, 2000, 163, 1150-4.	0.4	4
95	The association between education and risk of major cardiovascular events among prostate cancer patients: a study from the Diet, Cancer and Health study. Acta Oncológica, 2019, 58, 715-721.	1.8	3
96	Associations of low-dose aspirin or other NSAID use with prostate cancer risk in the Danish Diet, Cancer and Health Study. Cancer Causes and Control, 2020, 31, 139-151.	1.8	3
97	Characteristics of Patients in SPCG-15—A Randomized Trial Comparing Radical Prostatectomy with Primary Radiotherapy plus Androgen Deprivation Therapy in Men with Locally Advanced Prostate Cancer. European Urology Open Science, 2022, 41, 63-73.	0.4	3
98	Morbidity in patients with clinically localized prostate cancer managed with non-curative intent. A population-based case–control study. Prostate Cancer and Prostatic Diseases, 1999, 2, 253-256.	3.9	2
99	Length of life gained with surgical treatment of prostate cancer: A population-based analysis. Scandinavian Journal of Urology, 2015, 49, 275-281.	1.0	2
100	The use of transrectal ultrasound-guided biopsy following the introduction of prostate-specific antigen testing in Denmark: a population-based analysis. Scandinavian Journal of Urology, 2018, 52, 169-173.	1.0	2
101	Antidepressant prescriptions and associated factors in men with prostate cancer and their female partners. Journal of Cancer Survivorship, 2020, 15, 536-545.	2.9	2
102	The Association between Plasma Levels of Intact and Cleaved uPAR Levels and the Risk of Biochemical Recurrence after Radical Prostatectomy for Prostate Cancer. Diagnostics, 2020, 10, 877.	2.6	2
103	Biochemical response to enzalutamide therapy in patients with mCRPC following docetaxel and abiraterone treatment Journal of Clinical Oncology, 2014, 32, 202-202.	1.6	2
104	Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. Cancer Causes and Control, 2022, , 1.	1.8	2
105	Mortality of patients with clinically localized prostate cancer treated with observation for 10 years or longer: a population based registry study. Journal of Urology, 1999, 161, 524-8.	0.4	2
106	Plasma levels of intact and cleaved urokinase plasminogen activator receptor (uPAR) in men with clinically localised prostate cancer. Journal of Clinical Pathology, 2017, 70, 1063-1068.	2.0	1
107	Prognostic implication of gait function following treatment for spinal cord compression in men diagnosed with prostate cancer. Scandinavian Journal of Urology, 2019, 53, 222-228.	1.0	1
108	AZGP1 Protein Expression in Hormone-NaÃ⁻ve Advanced Prostate Cancer Treated with Primary Androgen Deprivation Therapy. Diagnostics, 2020, 10, 520.	2.6	1

#	Article	IF	CITATIONS
109	Temporal changes in causeâ€specific death in men with localised prostate cancer treated with radical prostatectomy: a populationâ€based, nationwide study. Journal of Surgical Oncology, 2021, 124, 867-875.	1.7	1
110	Long-term survival update of the Scandinavian Prostate Cancer Group 6 study: Bicalutamide 150 mg daily versus placebo in hormone-naÃ <sup>-</sup> ve, non-metastatic prostate cancer Journal of Clinical Oncology, 2015, 33, 2-2.	1.6	1
111	Efficacy of dexamethasone in reducing the postembolisation syndrome in men undergoing prostatic artery embolisation for benign prostatic hyperplasia: protocol for a single-centre, randomised, double-blind, placebo-controlled trial—the †DEXAPAE' study. BMJ Open, 2021, 11, e047878.	1.9	1
112	Prostate cancer in Denmark. Incidence, morbidity and mortality. Scandinavian Journal of Urology and Nephrology, Supplement, 1999, 203, 29-33.	0.0	1
113	Prescription rates for drugs used in treatment of benign prostatic hyperplasia and erectile dysfunction before and after prostate cancer diagnosis. Acta OncolA³gica, 2022, 61, 931-938.	1.8	1
114	Prostate Cancer in Denmark: A 50-Year Population-Based Study. Journal of Urology, 1998, 160, 1579-1579.	0.4	0
115	Reply to M. Nayan et al. Journal of Clinical Oncology, 2018, 36, 629-630.	1.6	0
116	The impact of positive surgical margins on salvage radiation or androgen deprivation therapy following radical prostatectomy $\hat{a} \in \hat{a}$ a nationwide study. Acta Oncol $\hat{A}^3$ gica, 2021, 60, 620-626.	1.8	0
117	Increasing use of radical prostatectomy for lower-risk prostate cancer in Denmark Journal of Clinical Oncology, 2014, 32, 149-149.	1.6	0
118	Biochemical response to ketoconazole therapy in post-chemotherapy mCRPC patients Journal of Clinical Oncology, 2014, 32, 174-174.	1.6	0
119	Urokinase plasminogen activator receptor (uPAR) as a novel biomarker in prostate cancer Journal of Clinical Oncology, 2015, 33, 183-183.	1.6	0
120	Survival trends in patients diagnosed with metastatic prostate cancer: A nationwide analysis Journal of Clinical Oncology, 2017, 35, 171-171.	1.6	0
121	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer Journal of Clinical Oncology, 2017, 2017, 12-12.	1.6	0
122	Nationwide analysis: Changes in the natural history of low risk localized prostate cancer Journal of Clinical Oncology, 2017, 35, 12-12.	1.6	0
123	Diagnostic characteristics of men harboring lethal prostate cancer: A population-based analysis Journal of Clinical Oncology, 2017, 35, 217-217.	1.6	0
124	Characteristics of finasteride users in comparison with nonusers: A Nordic nationwide study based on individualâ€level data from Denmark, Finland, and Sweden. Pharmacoepidemiology and Drug Safety, 2020, 29, 453-460.	1.9	0
125	Variations in serum P1NP, BAP and YKL-40 levels after start of treatment for advanced prostate cancer and the relation to prognosis. Journal of Clinical Oncology, 2004, 22, 4734-4734.	1.6	0
126	Reply by Authors. Journal of Urology, 2022, , 101097JU000000000000249103.	0.4	0

#	Article	IF	CITATIONS
127	Diagnostic Age, Age at Death and Stage Migration in Men Dying with or from Prostate Cancer in Denmark. Diagnostics, 2022, 12, 1271.	2.6	0